They call it the genetics of cancer, and researchers predict that one day it may lead to a cure.
The approach has already hinted at a number of potentially remarkable advances, such as creating individualised - even painless - treatments, and finding the shared genetic characteristics between such diseases as lung, colon and breast cancer.
Advertisement
While this may sound like science fiction, research in cancer genetics is already yielding dividends.
The wonders of Gleevec
The recent development of the highly effective leukaemia drug Gleevec is considered a milestone because it targets cancer cells, while leaving healthy tissue intact and causing few side effects, oncologists note.
Gleevec is used to treat chronic myeloid leukaemia. However, it has spawned a new class of "targeted-therapy" drugs, and is being tested on other cancers as well, such as paediatric bone cancer.
"For the first time, cancer researchers now have the necessary tools to probe the molecular anatomy of tumour cells in search of cancer-causing proteins," Dr Richard Klausner, director of the American National Cancer Institute, says of Gleevec, which was approved two years ago by the US Food and Drug Administration.
How drugs like Gleevec are developed
The basic method of developing drugs like Gleevec is fairly simple: isolate the genetic markers of cancer to find the ones that trigger the tumour. Then test various drugs against those trigger genes to see how they react. As a possible side benefit, the data collected through the process may one day illuminate genetic links between cancers.
"It may not be that all cancers can boil down to a certain gene, but it may be that certain sets of cancers, such as skin cancer, have shared characteristics," says Dr Peter Maslak, chief of the haematology laboratory at the Memorial Sloan-Kettering Cancer Centre in New York City.
"There's a tremendous amount of hope that within five or 10 years we're going to understand the genetics of most cancers," adds Dr Len Lichtenfeld, with the American Cancer Society's science department.
Prevention is still the best cure
But with April designated as Cancer Control Month in the US, Lichtenfeld emphasises the best cure for cancer remains prevention.
"Clearly there are a lot of new technologies and approaches, and a lot of them can help. But when we look at the big picture, what we can do right now is focus more on smoking, exercise and nutrition," he says.
About two-thirds of all cancers can be prevented based on lifestyle choices, Lichtenfeld says.
"There are huge returns in getting people to be healthy, stopping smoking and getting regular screenings," he says.
Advances in cancer detection
There have also been major advances in cancer detection.
The use of molecular testing, for instance, now allows doctors to find the smallest amounts of cancer in a person's body. Although this helps doctors to monitor cancer patients in remission to ensure the disease doesn't come back, it may also help detect cancer earlier in seemingly healthy people.
Traditionally, doctors had used microscopes to detect cancer cells. But this technology is inexact by today's standards, says Dr Jerald Radich, a researcher with the Fred Hutchinson Cancer Research Centre in Seattle.
Using a microscope, cancer cells aren't visible unless there are lots of them - about one tumour cell to 100 healthy cells. Molecular testing, by contrast, can find one tumour cell in a million healthy cells, leading to earlier detection and treatment, Radich says.
Advances due to leukaemia research
Many of the advances in cancer treatment result from research on leukaemia. The reason is fairly simple, Radich says. Because leukaemia resides in the blood, it is easier to extract and study than cancers that reside in tissue. Leukaemia research gained momentum in the 1970s, while research on other cancers lagged behind, he says.
But once researchers unlock the secrets of other cancer genes, a new set of questions may arise, Lichtenfeld says. For example, as targeted drugs become more refined, they may also become prohibitively expensive to develop.
Safety testing necessary
Lichtenfeld is also concerned that use of new therapies might outpace safety testing. A few years ago, for example, doctors thought bone marrow transplants might help women with breast cancer, but it wasn't until many of them had gone through this painful procedure that tests showed it didn't really help, he says.
"Hand-in-hand with all of this wonderful technology is the question how to use it. If you don't concentrate on how to use it early on, you may have to play catch-up for many years. You don't want it used haphazardly," Lichtenfeld says. – (HealthScout News)
Bookmark with:
What are social bookmarks?